Literature DB >> 16455805

Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.

Tiangang Li1, John Y L Chiang.   

Abstract

Bile acids and drugs activate pregnane X receptor (PXR) to induce CYP3A4, which is the predominant cytochrome P450 enzyme expressed in the liver and intestine and plays a critical role in detoxifying bile acids and drugs, and protecting against cholestasis. The aim of this study is to investigate the molecular mechanism of PXR cross talk with other nuclear receptors and coactivators in regulating human CYP3A4 gene transcription. Rifampicin dose dependently induced the CYP3A4 but inhibited small heterodimer partner (SHP) mRNA expression levels in primary human hepatocytes. Rifampicin strongly stimulated PXR and hepatocyte nuclear factor 4alpha (HNF4alpha) interaction, and CYP3A4 reporter activity, which was further stimulated by peroxisome proliferators-activated receptorgamma co-activator 1alpha (PGC-1alpha) and steroid receptor coactivator-1 (SRC-1) but inhibited by SHP. Mutation of the putative HNF4alpha binding site in the distal xenobiotic responsive element module did not affect CYP3A4 basal promoter activity and synergistic stimulation by PXR and HNF4alpha. Chromatin immunoprecipitation assays revealed that rifampicin-activated PXR recruited HNF4alpha and SRC-1 to the CYP3A4 chromatin. On the other hand, SHP reduced PXR recruitment of HNF4alpha and SRC-1 to the CYP3A4 chromatin. The human SHP promoter was stimulated by HNF4alpha and PGC-1alpha. Upon activation by rifampicin, PXR inhibited SHP promoter activity. Results suggest that PXR strongly induces CYP3A4 gene transcription by interacting with HNF4alpha, SRC-1, and PGC-1alpha. PXR concomitantly inhibits SHP gene transcription and maximizes the PXR induction of the CYP3A4 gene in human livers. Drugs targeted to PXR may be developed for treating cholestatic liver diseases induced by bile acids and drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455805      PMCID: PMC1524881          DOI: 10.1124/dmd.105.007575

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  32 in total

Review 1.  Regulation of cyp3a gene transcription by the pregnane x receptor.

Authors:  Bryan Goodwin; Matthew R Redinbo; Steven A Kliewer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

2.  Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.

Authors:  G P Hayhurst; Y H Lee; G Lambert; J M Ward; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

Authors:  W Xie; A Radominska-Pandya; Y Shi; C M Simon; M C Nelson; E S Ong; D J Waxman; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

4.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity.

Authors:  J L Staudinger; B Goodwin; S A Jones; D Hawkins-Brown; K I MacKenzie; A LaTour; Y Liu; C D Klaassen; K K Brown; J Reinhard; T M Willson; B H Koller; S A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.

Authors:  B Goodwin; E Hodgson; C Liddle
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

6.  Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha.

Authors:  Stephen S Ferguson; Yuping Chen; Edward L LeCluyse; Masahiko Negishi; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2005-06-02       Impact factor: 4.436

7.  Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes.

Authors:  Lionel Drocourt; Jean-Claude Ourlin; Jean-Marc Pascussi; Patrick Maurel; Marie-José Vilarem
Journal:  J Biol Chem       Date:  2002-05-03       Impact factor: 5.157

8.  Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.

Authors:  E G Schuetz; S Strom; K Yasuda; V Lecureur; M Assem; C Brimer; J Lamba; R B Kim; V Ramachandran; B J Komoroski; R Venkataramanan; H Cai; C J Sinal; F J Gonzalez; J D Schuetz
Journal:  J Biol Chem       Date:  2001-08-16       Impact factor: 5.157

9.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.

Authors:  B Goodwin; S A Jones; R R Price; M A Watson; D D McKee; L B Moore; C Galardi; J G Wilson; M C Lewis; M E Roth; P R Maloney; T M Willson; S A Kliewer
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

10.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors.

Authors:  T T Lu; M Makishima; J J Repa; K Schoonjans; T A Kerr; J Auwerx; D J Mangelsdorf
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

View more
  39 in total

Review 1.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 2.  Corepressors of agonist-bound nuclear receptors.

Authors:  Igor Gurevich; Anthony M Flores; Brian J Aneskievich
Journal:  Toxicol Appl Pharmacol       Date:  2007-06-14       Impact factor: 4.219

3.  LXR alpha transactivates mouse organic solute transporter alpha and beta via IR-1 elements shared with FXR.

Authors:  Masae Okuwaki; Tappei Takada; Yuki Iwayanagi; Saori Koh; Yoshiaki Kariya; Hiroshi Fujii; Hiroshi Suzuki
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

4.  Editor's Highlight: Neonatal Activation of the Xenobiotic-Sensors PXR and CAR Results in Acute and Persistent Down-regulation of PPARα-Signaling in Mouse Liver.

Authors:  Cindy Yanfei Li; Sunny Lihua Cheng; Theo K Bammler; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2016-07-13       Impact factor: 4.849

5.  The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha.

Authors:  Fu-Jun Liu; Xiulong Song; Dongfang Yang; Ruitang Deng; Bingfang Yan
Journal:  Biochem J       Date:  2008-01-01       Impact factor: 3.857

Review 6.  Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism.

Authors:  John Y L Chiang
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-02       Impact factor: 4.481

7.  Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes.

Authors:  Ritu Rana; Yuping Chen; Stephen S Ferguson; Grace E Kissling; Sailesh Surapureddi; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2010-01-19       Impact factor: 3.922

8.  Peroxisome proliferator-activated receptor-gamma coactivator-1alpha activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner.

Authors:  Dong-Ju Shin; Timothy F Osborne
Journal:  J Biol Chem       Date:  2008-04-02       Impact factor: 5.157

9.  Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform.

Authors:  Thomas J Long; Patrick A Cosgrove; Robert T Dunn; Donna B Stolz; Hisham Hamadeh; Cynthia Afshari; Helen McBride; Linda G Griffith
Journal:  Drug Metab Dispos       Date:  2016-09-12       Impact factor: 3.922

10.  Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.

Authors:  Ehab S Eldesoky; Sherif I Kamel; Ahlam M Farghaly; Madiha Y Bakheet; Mohsen A Hedaya; Jean-Pascal Siest
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.